

## Mesoblast CEO Silviu Itescu wins CEO of the Year by Biotech Daily

**Melbourne, Australia; December 18, 2025:** Australia's leading biotech publication Biotech Daily has awarded Mesoblast CEO Professor Silviu Itescu its prestigious CEO of the Year award for 2025.

The publication announced the award today and presented Professor Itescu with an award certificate.

Biotech Daily Editor David Langsam said the award was in recognition of the company's significant milestones achieved, especially in the past 12 months.

"The Biotech Daily CEO of the Year for 2025 has been awarded to Mesoblast chief executive Prof Silviu Itescu for tirelessly backing Ryoncil for graft versus host disease over many years, winning US Food and Drug Administration approval, and this year seeing significant revenues flow from this hard work," Biotech Daily said in award certificate.

Professor Itescu thanked Biotech Daily and its editor David Langsam and journalist Tim Boreham of Dr Boreham's Crucible for the award, which capped off a historic year of achievement for the company.

"I am honoured to win this award for CEO of the Year. Although this is a personal award, it is also recognition for the efforts of a hard-working team which is determined to further develop new products and bring them in a commercially successful way to those who need these new therapies," he said.

### About Mesoblast

Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast's Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at [www.ryoncil.com](http://www.ryoncil.com).

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see [www.mesoblast.com](http://www.mesoblast.com), LinkedIn: Mesoblast Limited and X: @Mesoblast

### Media – Australia

BlueDot Media  
Steve Dabkowski  
T: +61 419 880 486  
E: [steve@bluedot.net.au](mailto:steve@bluedot.net.au)

**Mesoblast Limited**  
ABN 68 109 431 870  
[www.mesoblast.com](http://www.mesoblast.com)

**Corporate Headquarters**  
Level 38  
55 Collins Street  
Melbourne 3000  
Victoria Australia  
T +61 3 9639 6036  
F +61 3 9639 6030

**United States Operations**  
1114 Avenue of the Americas  
4th Floor  
New York, NY 10036  
USA  
T +1 212 880 2060  
F +1 212 880 2061

**Asia**  
21 Biopolis Road  
#01-22 Nucleos (South Tower)  
SINGAPORE 138567  
T +65 6570 0635  
F +65 6570 0176